使用GORE TAG或顺应性GORE TAG行胸主动脉腔内修复术的远期结局与晚期并发症
本回顾性观察研究纳入单中心175例连续接受GORE TAG或顺应性GORE TAG行胸主动脉腔内修复术的患者,平均随访46.5±33.1个月,30天死亡率为2.86%,10年总生存率为42.4±8.4%,9年免于主动脉相关死亡率为95.0±2.1%,晚期并发症发生率为13.1%,TAG与CTAG组间免于晚期并发症和再干预无显著差异。
要点
- 30天死亡率为2.86%,10年总生存率为42.4±8.4%。
- 9年免于主动脉相关死亡率为95.0±2.1%。
- 晚期并发症发生率为13.1%,14例因内漏、假腔扩大或支架移植物诱发新破口行腔内再干预。
核心结论
- 使用GORE TAG或顺应性GORE TAG行胸主动脉腔内修复术是治疗胸主动脉瘤和主动脉夹层的安全有效方法。
- 随访10年期间总生存率较低,但主动脉相关死亡风险也较低。
- TAG与CTAG组间免于晚期并发症和再干预无显著差异。
- 需要进一步研究晚期并发症的治疗。
研究设计与样本
- 回顾性观察研究,分析单中心所有连续年龄20岁及以上接受GORE TAG或顺应性GORE TAG行胸主动脉腔内修复术的患者数据。
- 2011年1月至2021年12月间331例患者接受TEVAR,其中175例连续接受GORE TAG或顺应性GORE TAG治疗的患者被纳入。
- 手术标准未偏离全球标准,原则上按制造商说明使用TAG或CTAG行TEVAR。
- 主要结局为10年总生存率和10年免于主动脉相关死亡率。
主要发现
- 患者平均年龄72.1±9.3岁,动脉瘤占61.7%,慢性夹层占38.3%。
- 157例近端锚定区≥3区,18例<3区。
- 平均随访时间46.5±33.1个月,30天死亡率为2.86%。
- 3年、5年、7年、10年总生存率分别为76.9±3.4%、63.4±4.1%、55.9±4.9%、42.4±8.4%。
- 3年、5年、7年、9年免于主动脉相关死亡率分别为97.4±1.3%、95.0±2.1%、95.0±2.1%、95.0±2.1%;晚期并发症发生于23例(13.1%),14例因内漏、假腔扩大或支架移植物诱发新破口行腔内再干预,3例需开放转换,6例未再干预观察。
临床怎么用
- 原文结论认为使用GORE TAG或顺应性GORE TAG行TEVAR是治疗胸主动脉瘤和主动脉夹层的安全有效方法。
- 原文指出需要进一步研究晚期并发症的治疗。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Previous clinical studies have reported on the short- and mid-term prognoses of thoracic endovascular aortic repair (TEVAR) using the GORE thoracic aortic graft (TAG) or conformable GORE TAG. We evaluated the long-term prognoses of patients who underwent TEVAR using the GORE TAG or conformable GORE TAG in a real-world setting. MATERIALS AND METHODS: This retrospective observational study analyzed the data of all consecutive patients aged 20 years or older who underwent TEVAR using either the GORE TAG or the conformable GORE TAG at a single center. The surgical criteria did not deviate from global standards. In principle, TEVAR was performed with the TAG or conformable thoracic aortic graft (CTAG) according to the manufacturer's instructions. The primary outcomes of this study were the 10-year overall survival rate and the rate of freedom from aorta-related deaths at 10 years. RESULTS: Between January 2011 and December 2021, 331 patients underwent TEVAR, of whom 175 consecutive patients treated with TEVAR using either the GORE TAG or the conformable GORE TAG were enrolled. The mean age of the patients was 72.1 ± 9.3 years. In addition, the aneurysm and chronic dissection were 61.7% and 38.3%, respectively. Of all patients, 157 had a proximal landing zone ≥3, and 18 had a zone <3. The mean follow-up time was 46.5 ± 33.1 months. The 30-day mortality rate was 2.86%. The 3-, 5-, 7-, and 10-year overall survival rates were 76.9 ± 3.4%, 63.4 ± 4.1%, 55.9 ± 4.9%, and 42.4 ± 8.4%, respectively. The rate of freedom from aorta-related deaths at 3, 5, 7, and 9 years was 97.4 ± 1.3%, 95.0 ± 2.1%, 95.0 ± 2.1%, and 95.0 ± 2.1%, respectively. Late complications occurred in 23 (13.1%) patients. Endovascular re-intervention was performed because of endoleak, false lumen enlargement, or stent graft-induced new entry tear in 14 patients. Three patients required open conversion, and 6 were observed without re-intervention. CONCLUSIONS: Thoracic endovascular aortic repair using the GORE TAG or conformable GORE TAG is a safe and effective procedure for the treatment of thoracic aortic aneurysms and aortic dissection.Clinical ImpactThoracic endovascular aortic repair using the GORE thoracic aortic graft (TAG) or conformable GORE TAG is a safe and effective procedure for the treatment of thoracic aortic aneurysms and aortic dissection. The 30-day mortality rate was 2.86%. During 10 years of follow-up, the overall survival rate was low; however, the risk of aorta-related deaths was also low. No significant differences in freedom from late complications and re-intervention are seen between the TAG and conformable thoracic aortic graft (CTAG) groups. Further investigations into the treatment of late complications are required.
引用
- Tsushima S, Shibata T, Iba Y, et al. Long-Term Outcomes and Late Complications of Thoracic Endovascular Aortic Repair Using the GORE TAG or Conformable GORE TAG. J Endovasc Ther. 2024. PMID: 39692144. doi:10.1177/15266028241305960
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。